Denali Therapeutics annual ebitda margin
2018
2019
2020
2021
2022
2023
Denali Therapeutics EBITDA Margin Growth & History (DNLI)
Denali Therapeutics's ebitda margin was −54.45% for fiscal 2023.
View full Denali Therapeutics company overviewDenali Therapeutics annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2023 | 2023-12-31 | −54.45% | +259.99 pp |
| 2022 | 2022-12-31 | −314.43% | +275.73 pp |
| 2021 | 2021-12-31 | −590.17% | −611.40 pp |
| 2020 | 2020-12-31 | 21.23% | +800.84 pp |
| 2019 | 2019-12-31 | −779.61% | −749.43 pp |
| 2018 | 2018-12-31 | −30.18% | — |
Denali Therapeutics quarterly ebitda margin
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q2.26
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −3,523.09% | — |
| Q3 2023 | 2023-09-30 | −8,806.47% | +48446.25 pp |
| Q2 2023 | 2023-06-30 | 58.74% | +171.82 pp |
| Q1 2023 | 2023-03-31 | −315.21% | −162.34 pp |
| Q4 2022 | 2022-12-31 | −986.87% | −387.33 pp |
| Q3 2022 | 2022-09-30 | −57,252.72% | −55674.55 pp |
| Q2 2022 | 2022-06-30 | −113.08% | +146.83 pp |
| Q1 2022 | 2022-03-31 | −152.87% | +719.54 pp |
| Q4 2021 | 2021-12-31 | −599.54% | −677.26 pp |
| Q3 2021 | 2021-09-30 | −1,578.16% | −960.78 pp |
| Q2 2021 | 2021-06-30 | −259.91% | +757.68 pp |
| Q1 2021 | 2021-03-31 | −872.41% | +756.48 pp |
| Q4 2020 | 2020-12-31 | 77.71% | +1269.98 pp |
| Q3 2020 | 2020-09-30 | −617.38% | −260.08 pp |
| Q2 2020 | 2020-06-30 | −1,017.59% | +473.87 pp |
| Q1 2020 | 2020-03-31 | −1,628.89% | −653.33 pp |
| Q4 2019 | 2019-12-31 | −1,192.27% | −1253.62 pp |
| Q3 2019 | 2019-09-30 | −357.31% | +2624.87 pp |
| Q2 2019 | 2019-06-30 | −1,491.46% | +1877.90 pp |
| Q1 2019 | 2019-03-31 | −975.55% | +2908.07 pp |
| Q4 2018 | 2018-12-31 | 61.35% | — |
| Q3 2018 | 2018-09-30 | −2,982.18% | — |
| Q2 2018 | 2018-06-30 | −3,369.36% | — |
| Q1 2018 | 2018-03-31 | −3,883.62% | — |
Denali Therapeutics ebitda margin trends
Over the last five fiscal years, Denali Therapeutics's ebitda margin decreased from −30.18% to −54.45%, a change of −24.27 percentage points. The latest reported quarter, Q2 2026, shows −3,523.09%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Denali Therapeutics source filings ↗